Healthcare and life-sciences grants in Canada: see what you qualify for
Answer a few quick questions and watch the map narrow to the CIHR, SR&ED, IRAP, Genome Canada, and provincial programs your business can actually get. Free, no account.
Updated July 16, 2026
Canadian healthcare and life-sciences companies fund R&D by building a stack of non-dilutive programs, not by winning one big grant. The core four are NRC IRAP (upfront cash and a free advisory relationship), SR&ED (a 35% refundable tax credit for Canadian-controlled private corporations on up to $6 million of R&D under Budget 2025), CIHR (health research funding, usually through an academic partner), and provincial credits and funds like Ontario's OITC and LSSUF or Quebec's CRIC. Start with IRAP, claim SR&ED every year, then layer CIHR, Genome Canada, DHDP, or BioCanRx once you have clinical traction. Companies that do this recover 40% to 65% of cumulative R&D costs over 3 to 5 years.
Match the program to your business
The programs you should prioritise depend on what kind of healthcare organisation you run. Four archetypes cover most Canadian applicants. Find yours, then use the map above to confirm the specific programs you qualify for.
Lead with IRAP, add Infoway and SR&ED
You are building in the fastest-growing segment of Canadian health funding, with more programs available than almost any other archetype. IRAP is your fastest path to non-dilutive cash and advisory support, and digital health is a stated priority for NRC's Industrial Technology Advisors. SR&ED applies broadly to digital health R&D: algorithm development, clinical validation of novel AI outputs, and interoperability protocol work. Canada Health Infoway's Connected Care Innovation Grant (up to $40,000, rolling intake) is low-friction and lends clinical credibility that provincial health authorities recognise.
Where early-stage teams over-invest: CIHR. Without an academic partner and 12 months of runway, its 6 to 9 month cycle and roughly 15% to 17% success rate make it a poor first target. Build the IRAP relationship first, file SR&ED in year one, and return to CIHR partnership programs once you have a university co-applicant. Route: run the map, then start with IRAP and Infoway.
SR&ED at 35% is the baseline, then layer partnerships
You have access to Canada's deepest non-dilutive well and its most complex application landscape. SR&ED at a 35% refundable rate on up to $6 million (post-Budget 2025) makes Canada one of the most generously subsidised R&D environments in the G7 for CCPCs, and Budget 2025 restored capital-equipment eligibility, which matters for cell-culture equipment, analytical instruments, and bioreactors. File SR&ED from the moment R&D begins. IRAP covers commercialisation and product-development activities SR&ED does not.
CIHR's Partnering for Impact Catalyst Grant (up to $150,000) is the right, less-competitive entry point for academic partnerships. If your work has a genomics dimension, Genome Canada's GAPP program ($1 million to $3 million via your regional centre) is substantial and under-applied. Quebec biotechs gain an extra edge: the CRIC at 14% stacks with federal SR&ED. Route: file SR&ED every year, add IRAP, then CIHR Catalyst or Genome Canada.
IRAP plus a provincial scale-up fund, then SR&ED
Multi-site operators and manufacturers have the organisational maturity that larger programs are designed for; the challenge is sequencing, not eligibility. Ontario's Life Sciences Scale-up Fund (up to $2.5 million, covering 33% of eligible costs for SMEs with 5 to 500 employees) pairs cleanly with an IRAP project on the technology-development components and annual SR&ED on the rest. For transformative biomanufacturing well above that scale, with strong private co-investment, the federal Strategic Response Fund starts at a $10 million contribution.
Factor Health Canada device timelines into your IRAP project scope, regulatory work may be eligible. Secure the faster provincial program first (3 to 4 months), use that traction to strengthen the IRAP application, then file SR&ED at year-end. Route: provincial scale-up fund first, then IRAP, then SR&ED.
IRAP and SR&ED apply only if you are building something new
You sit in a narrower window than research-intensive companies, and that is not a dead end, it means your optimal programs are less competitive because fewer applicants realise they qualify. Off-the-shelf equipment with no customisation does not qualify for IRAP or SR&ED. Where they open up is genuine development: integrating two systems that do not natively connect, customising a telehealth platform, or building diagnostic AI into your workflow. Document the technical uncertainty from day one.
The Infoway Connected Care Innovation Grant (up to $40,000) is designed for clinics adopting digital solutions like patient portals, virtual care, and e-prescribing, with a low application burden relative to its value. Route: run the map to check the build qualifies, then Infoway plus SR&ED.
For most Canadian healthcare companies the best first program is IRAP, not CIHR or SR&ED. It provides upfront cash through monthly reimbursements, a free advisory relationship with an assigned ITA who maps your whole funding stack, and approval in 9 to 20 business days, while SR&ED is retroactive and CIHR runs a 15% to 17% success rate over 6 to 9 months. Start with IRAP, then map SR&ED and provincial programs in parallel.
Want a heads-up before CIHR, Genome Canada, and IRAP deadlines close? Run the 2-minute match at the top of this page, save the programs that fit, and you'll get deadline alerts for every program you save.
Major federal healthcare funding programs
SR&ED (Scientific Research & Experimental Development)
SR&ED is Canada's largest single source of R&D support for healthcare companies, delivered by the Canada Revenue Agency as a refundable tax credit on eligible salaries, materials, subcontractor costs and, as of Budget 2025, capital equipment used 90% or more for R&D. Qualifying healthcare work includes developing novel assays, creating new medical devices, formulating therapeutics, designing diagnostic algorithms, and process innovation in biomanufacturing. Canadian-controlled private corporations claim the enhanced 35% rate on up to $6 million of expenditures (the limit Budget 2025 raised directly from $3 million), a maximum enhanced credit of $2.1 million a year. Claims must be filed within 18 months of fiscal year-end. Combined with the best provincial credits, total recovery can reach roughly 65% of eligible expenditures.
Source: Canada Revenue Agency, SR&ED Tax Incentive Program; Department of Finance Canada, Budget 2025.NRC IRAP (Industrial Research Assistance Program)
IRAP is Canada's premier innovation program for SMEs, with $562 million in total expenditures in 2024-25 (including $437 million in grants). It provides both advisory services through an assigned Industrial Technology Advisor and non-repayable funding, covering up to 80% of technical salaries and 50% of subcontractor costs. IRAP is exceptionally relevant for medical devices, digital health platforms, biotech products, and diagnostic tools, and it covers commercialisation activities that SR&ED does not, which makes the two ideal stacking partners. Awards are typically modest: the median actual award is about $75,000 and up to $1 million is typical, with a $10 million ceiling reserved for major capital projects. Approvals run 9 to 20 business days, and budgets reset April 1 each year, so April to June is the strongest window to apply.
Source: National Research Council Canada, IRAP; GrantCompass catalog record (Industrial Research Assistance Program).CIHR (Canadian Institutes of Health Research)
CIHR is Canada's federal health-research funding agency, and it invested $1.336 billion in grants and awards in 2024-25. Its flagship Project Grant competition funds academic-led research, with the Fall 2024 competition funding 453 grants totalling about $411 million and awards averaging roughly $980,000 over 4.5 years. Companies usually participate as co-applicants or collaborators alongside university researchers. The most practical industry entry point is the Partnering for Impact Catalyst Grant (up to $150,000, including a $125,000 base plus $25,000 for equity-focused engagement), which requires a non-academic partner contribution and is far less competitive than the main Project Grant stream. SPOR Networks require 1:1 matching from non-federal partners, including industry, with up to 50% as in-kind contributions. Beyond Project Grants, CIHR runs specialised streams worth knowing: the Health System Impact Fellowship embeds PhD and postdoctoral talent in health organisations, including companies, with salary support of $50,000 to $70,000 a year for 1 to 3 years, and the CIHR-NSERC Collaborative Health Research Projects program funds work that bridges health and engineering. Budget 2024 added $540 million over five years to expand CIHR's capacity.
Source: CIHR 2024-25 Departmental Results Report; GrantCompass catalog record #545 (CIHR Partnering for Impact Catalyst Grant).Genome Canada and the regional Genome Centres
Genome Canada has facilitated $4 billion in total research investment since 2000 ($1.6 billion federal plus $2.4 billion in co-funding), producing 531 patents and 131 spinoff companies. It funds large-scale genomics projects through six regional centres: Ontario Genomics, Genome Quebec, Genome BC, Genome Alberta, Genome Prairie, and Genome Atlantic. The Genomic Applications Partnership Program (GAPP) funds public-private innovation, typically $1 million to $3 million, with applications submitted through your regional centre, which often co-develops the application at no charge. The $175.1 million Canadian Genomics Strategy (February 2025) and the $200 million Canadian Precision Health Initiative (March 2025, $81 million federal) to sequence more than 100,000 genomes are the major new health-genomics investments. Genome Canada has invested $715 million specifically in health genomics.
Source: Genome Canada, Results and Impact.DHDP (Digital Health and Discovery Platform)
DHDP is a $25 million federal investment administered through the Terry Fox Research Institute to build pan-Canadian digital health data infrastructure. Individual projects receive $1 million to $7 million for AI-ready health data systems, federated learning, and clinical decision-support tools. DHDP specifically targets interoperable health data that connects across provincial health networks, a known gap, and it complements IRAP (which funds product development) by funding the data-infrastructure layer. Companies building health analytics, clinical AI, or population-health platforms should explore it alongside IRAP and SR&ED.
Source: Digital Health and Discovery Platform (DHDP).Canada Health Infoway, Connected Care Innovation Grant
Infoway funds projects that improve connected care and digital-health adoption across the health system. Its Connected Care Innovation Grant provides up to $40,000 per project, on a rolling intake, for organisations implementing or scaling interoperable digital-health solutions: patient portals, virtual care, e-prescribing, and health information exchange. The dollar amount is modest, but a funded Infoway project comes with access to clinical validation frameworks, the ACCESS Health adopter network, and endorsement that accelerates procurement by provincial health authorities. For early-stage digital-health companies, it often unlocks larger IRAP or provincial funding by proving real-world clinical adoption.
Source: Canada Health Infoway.BioCanRx, CFI, and the Strategic Response Fund
Three more federal programs fund specific situations. BioCanRx, Canada's cancer-immunotherapy network, holds a $38 million Strategic Science Fund commitment over five years and has funded 60 projects including 12 clinical trials, leveraging $115.2 million in partner contributions. Companies participate through industry-academic partnerships. The Canada Foundation for Innovation (CFI) funds research infrastructure; companies cannot apply directly, but its Research Facilities Navigator lists more than 800 publicly funded labs where you can access equipment for validation and prototyping, and the John R. Evans Leaders Fund covers up to 40% of projects up to $2 million. The Strategic Response Fund (formerly the Strategic Innovation Fund) backs large-scale biomanufacturing, with recent health investments of $62 million to Entos Pharmaceuticals, $49 million to Aspect Biosystems, and $49.9 million to STEMCELL Technologies; the minimum contribution is $10 million on projects of $20 million or more.
Source: BioCanRx; Canada Foundation for Innovation; Innovation, Science and Economic Development Canada (Biomanufacturing and Life Sciences Strategy).Federal healthcare programs at a glance
| Program | Amount | Type | Best for | Timeline |
|---|---|---|---|---|
| SR&ED | Up to $2.1M/yr refundable (35% on $6M) | Tax credit | All healthcare R&D | After fiscal year-end |
| NRC IRAP | Median $75K, up to $1M typical ($10M capital ceiling) | Non-repayable grant | SME product development | 9 to 20 business days |
| CIHR Project Grant | ~$980K over 4.5 years | Grant | Academic-industry research | Biannual competitions |
| CIHR Catalyst (Partnering for Impact) | Up to $150K | Grant | First academic partnership | Rounds |
| Genome Canada GAPP | $1M to $3M | Research funding | Genomics, precision medicine | Via regional centre |
| DHDP | $1M to $7M per project | Research funding | Health data infrastructure | Competitive rounds |
| BioCanRx | Project-based (from $38M network) | Research funding | Cancer immunotherapy | Open-call competitions |
| Strategic Response Fund | $10M+ contribution | Large-scale contribution | Biomanufacturing ($20M+ projects) | Months, invite-based |
| Infoway Connected Care | Up to $40K | Innovation grant | Digital-health interoperability | Rolling intake |
How to stack healthcare funding programs
Most funded healthcare companies do not rely on a single program. They build a stack, a deliberate sequence that compounds non-dilutive capital at each stage. IRAP pays you upfront through monthly reimbursements while a project runs; SR&ED recovers a share of the rest after year-end. The one hard rule is no double-dipping: you must reduce your SR&ED eligible expenditures by the IRAP assistance received on the same costs.
Worked example: Ontario CCPC, $400,000 in R&D
| Step | Amount |
|---|---|
| Total eligible R&D | $400,000 |
| IRAP grant (80% of a $150K salary portion) | $120,000 |
| Remaining eligible for SR&ED ($400K less $120K) | $280,000 |
| Federal SR&ED at 35% | $98,000 |
| Ontario OITC at 8% | $22,400 |
| Total recovered | $240,400 (60.1%) |
Worked example: Quebec biotech, $500,000 in R&D
Quebec offers Canada's most generous provincial R&D credits. Federal SR&ED at 35% on $500,000 returns $175,000; the Quebec CRIC at 14% adds $70,000 (refundable); Quebec salary credits add an estimated $37,500. Total recovered is about $282,500, or 56.5%. The CRIC stacks directly with the federal 35% for a combined 49% before salary credits.
The four-stage funding stack
- Validation ($50K to $500K). IRAP for upfront cash, plus a CIHR Catalyst Grant (up to $150K) if an academic partner exists, or an Infoway Connected Care Grant (up to $40K) for digital-health validation. Focus: prove feasibility, build the ITA relationship.
- Development ($200K to $2M). Add SR&ED on all R&D net of IRAP (35% plus provincial), a larger IRAP follow-on, and provincial programs like Ontario LSIF, Quebec Fonds Impulsion, or Alberta AICE.
- Clinical validation and scale ($500K to $10M). Layer CIHR Project Grants, Genome Canada GAPP for genomics, DHDP for data infrastructure, or BioCanRx for immunotherapy. Focus: clinical trials, health-system pilots, regulatory approval.
- Commercialisation ($10M+). Access the Strategic Response Fund for large-scale biomanufacturing and Ontario LSSUF for manufacturing scale-up. SR&ED continues throughout, up to $2.1M a year.
For an Ontario healthcare CCPC, the strongest stack is IRAP plus federal SR&ED (35%) plus the Ontario OITC (8%), because it recovers more than 60% of eligible R&D costs without an academic partner, a competitive grant application, or any equity dilution. Quebec companies swap the OITC for the CRIC (14%), Canada's highest provincial R&D credit.
Provincial life-sciences programs
Provincial programs are often faster to access and less competitive than federal ones, and most funded companies use both federal and provincial support at once. The trade-off is geographic: you must operate in the province, and maximums are smaller. Ontario and Quebec run the two largest clusters.
| Province | Lead program | Amount | Best suited for |
|---|---|---|---|
| Ontario | LSSUF (Life Sciences Scale-up Fund) | Up to $2.5M (33% of costs) | SME scale-up, 5 to 500 employees |
| Ontario | LSIF + OITC (8% on SR&ED) | Up to $500K co-investment | Early-stage life sciences |
| Quebec | CRIC + Fonds Impulsion | 14% credit + $200M fund | R&D-intensive, early-stage biopharma |
| British Columbia | adMare Tx Accelerator + Genome BC | Seed capital + lab access | Early biotech, cell and gene therapy |
| Alberta | Alberta Innovates AICE | $200K to $600K | Clinical validation, market access |
| Atlantic | Invest Nova Scotia + Genome Atlantic | Fund-based (life-sciences focus) | Early-stage tech and bioscience |
Ontario unified its commercialisation support under Life Sciences Central (October 2025), bringing together MaRS, OBIO, and TIAP. Quebec's Life Sciences Strategy 2025-2028 commits more than $270 million, including the $200 million Fonds Impulsion for seed-stage companies, delivered via ecosystem-partner referral. British Columbia captured close to half of all Canadian life-sciences venture capital in 2024-25. Alberta's AICE streams fund concepts, validation, and market access, several co-funded 50/50 with partners like AGE-WELL.
Source: Government of Ontario (LSIF, LSSUF, OITC); Investissement Quebec and Government of Quebec (CRIC, Fonds Impulsion); adMare BioInnovations; Alberta Innovates; Invest Nova Scotia.Common healthcare grant application pitfalls
Healthcare funding is real but easy to misread. The mistakes that cost applicants the most:
- Confusing clinical validation with SR&ED. Testing a drug using established clinical protocols does not qualify. Developing a novel assay, a new testing methodology, or overcoming a specific technical uncertainty does.
- Missing the 18-month SR&ED filing deadline. Claims must be filed within 18 months of fiscal year-end. There are no extensions, and late claims are permanently forfeited.
- No contemporaneous documentation. The single biggest reason SR&ED claims are reduced. Record hypotheses, experiments, and results as they happen, not retroactively at year-end.
- Applying for IRAP in Q3 or Q4. IRAP budgets reset April 1 and deplete through the year. Apply April to June for the best odds.
- Ignoring provincial credits. Many companies claim only federal SR&ED when stacking Ontario's OITC (8%), Quebec's CRIC (14%), or Alberta's AICE programs would add materially to the recovery.
- Not engaging an IRAP ITA early. Industrial Technology Advisors help identify every applicable program, not just IRAP. This free advisory relationship is the most valuable single entry point into the ecosystem.
How much Canada invests in healthcare innovation
Canada invests well over $2.5 billion a year in healthcare innovation across multiple channels. The headline figures below come from official government reports and departmental results (see Sources).
"Basic research is our future. It lays the groundwork for discoveries that will revolutionize health care in 10 or 20 years. But we must also invest in projects that will immediately improve the lives of Canadians."
Dr. Paul Hébert, President, Canadian Institutes of Health Research, University of Ottawa, February 2025More on healthcare funding in Canada
Government healthcare-innovation funding runs past $2.5 billion a year
Canada funds healthcare innovation through several parallel channels rather than one budget line. CIHR alone invested $1.336 billion in 2024-25. NRC IRAP spent $562 million (including $437 million in grants) across all sectors, with healthcare a stated priority. The $2.2 billion Biomanufacturing and Life Sciences Strategy funds domestic vaccine and therapeutics capacity, including the $250 million Canada Biomedical Research Fund. Genome Canada has facilitated $4 billion since 2000. Provincial programs add hundreds of millions more through Ontario's LSIF and LSSUF, Quebec's $270 million life-sciences strategy, and Alberta Innovates' AICE programs. Most companies never touch the largest programs; the practical money for an SME is IRAP, SR&ED, and one or two provincial add-ons.
Budget 2025 doubled the SR&ED enhanced-rate limit for healthcare R&D
Budget 2025 raised the enhanced-rate expenditure limit directly from $3 million to $6 million, lifting the maximum annual refundable credit from $1.05 million to $2.1 million. Capital expenditures (equipment used 90% or more for SR&ED) are eligible again after being excluded since 2014, which matters for healthcare companies buying lab equipment, imaging devices, or manufacturing tools. Public corporations can now access the enhanced 35% rate for the first time. Phase-out thresholds were also raised: prior-year taxable income from $500,000 to $800,000, and taxable capital from a $10 million to $50 million band up to a $15 million to $75 million band. For a healthcare CCPC, the practical effect is a bigger refundable cheque on the same R&D, and lab and imaging equipment back on the eligible list.
Healthcare startups can combine IRAP and SR&ED on the same project
IRAP and SR&ED are the most valuable pairing for most healthcare innovators, and they work together by design. IRAP provides upfront cash through monthly reimbursements during the project; SR&ED provides tax credits after fiscal year-end. You must reduce your SR&ED eligible expenditures by the IRAP assistance received, so there is no double-dipping on the same costs, but IRAP covers broader commercialisation activities that SR&ED does not. A well-structured claim for an Ontario CCPC can recover more than 60% of eligible R&D costs through IRAP, federal SR&ED at 35%, and the provincial OITC at 8%. The sequencing is simple: take IRAP cash as the project runs, then claim SR&ED on the residual costs at year-end.
CIHR funds industry through partnerships, not direct company grants
CIHR funds industry-academic collaborations rather than paying companies directly. The Partnering for Impact Catalyst Grant (up to $150,000) is the main entry point and specifically fosters industry partnerships and commercialisation potential. CIHR's SPOR Networks require 1:1 matching from non-federal partners, including industry, with up to 50% as in-kind contributions. Companies typically participate as co-applicants or collaborators alongside university researchers, sharing risk and gaining access to clinical infrastructure. In the Fall 2024 Project Grant competition, CIHR funded 453 grants totalling about $411 million, with awards averaging roughly $980,000 over 4.5 years. For a company, the realistic path is a university co-applicant plus a Catalyst Grant before attempting the main Project Grant stream.
The GrantCompass catalog, in numbers
Across the 80 healthcare and life-sciences programs in our catalog (tagged healthcare, life-sciences, biotechnology, or medical-devices), the median maximum award is $500,000. Most are grants (50 of 80); four are tax credits, and the remainder are accelerator programs, loans, and awards. That spread is why the stack matters: the median program alone rarely covers a healthcare R&D budget, but two or three layered together often recover the majority of it. Use the map at the top of the page to see which of these programs match your business.
Sources and references
All funding amounts, program details, and statistics on this page are drawn from official Canadian government publications and verified program administrators.
- CIHR 2024-25 Departmental Results Report. Confirms $1.336B total investment, 453 Project Grants funded ($411M), Budget 2024 allocation of $540M over 5 years.
- SR&ED Tax Incentive Program, Canada Revenue Agency. Expenditure limit, enhanced rate, capital-equipment eligibility, and filing deadlines.
- Budget 2025, Department of Finance Canada. SR&ED expenditure limit raised from $3M to $6M, capital equipment restored, public-corporation eligibility, phase-out threshold increases.
- NRC Industrial Research Assistance Program (IRAP), National Research Council Canada. $562M total expenditures in 2024-25, $437M in grants.
- Genome Canada, Results and Impact. $4B in total research investment since 2000, 531 patents, 131 spinoff companies, $715M in health genomics.
- Biomanufacturing and Life Sciences Strategy, Innovation, Science and Economic Development Canada. $2.2B initiative, $250M CBRF, Strategic Response Fund investments in Entos ($62M), Aspect Biosystems ($49M), STEMCELL ($49.9M).
- BioCanRx, Canada's Immunotherapy Network. $38M Strategic Science Fund commitment, 60 projects funded, $115.2M in partner contributions.
- Digital Health and Discovery Platform (DHDP). $25M federal investment, $1M to $7M per project.
- Canada Health Infoway. Connected Care Innovation Grants (up to $40K), ACCESS Health network.
- Dr. Paul Hébert, CIHR President, on the future of health-care research, University of Ottawa, February 2025.
Get healthcare funding matches and deadline alerts
CIHR, Genome Canada, and IRAP deadlines shift through the year. Join the list and we will flag the grants, tax credits, and provincial programs that fit your healthcare or life-sciences project before they close.
Free. No spam. Unsubscribe anytime.
See your healthcare funding matches in 2 minutes
Answer a few quick questions about your business and see the grants, tax credits, and programs matched to your sector, stage, and province, free.
Find my funding matches →